Sage Therapeutics, Inc. (NASDAQ:SAGE) – SunTrust Banks lifted their FY2017 earnings estimates for shares of Sage Therapeutics in a research note issued on Tuesday. SunTrust Banks analyst E. Nash now anticipates that the biopharmaceutical company will post earnings of ($6.63) per share for the year, up from their prior forecast of ($6.75). SunTrust Banks currently has a “Buy” rating and a $82.00 target price on the stock. SunTrust Banks also issued estimates for Sage Therapeutics’ Q4 2017 earnings at ($1.54) EPS, FY2018 earnings at ($5.62) EPS, FY2019 earnings at ($4.63) EPS, FY2020 earnings at ($3.04) EPS and FY2021 earnings at ($0.10) EPS.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same quarter last year, the business earned ($1.08) earnings per share.

ILLEGAL ACTIVITY WARNING: “SunTrust Banks Research Analysts Boost Earnings Estimates for Sage Therapeutics, Inc. (SAGE)” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/15/suntrust-banks-research-analysts-boost-earnings-estimates-for-sage-therapeutics-inc-sage.html.

Several other brokerages have also weighed in on SAGE. Cowen and Company decreased their price objective on Sage Therapeutics from $100.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday. J P Morgan Chase & Co decreased their price objective on Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating on the stock in a report on Tuesday. Canaccord Genuity decreased their price objective on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating on the stock in a report on Tuesday. Stifel Nicolaus began coverage on Sage Therapeutics in a report on Wednesday, August 9th. They set a “buy” rating and a $104.00 price objective on the stock. Finally, Leerink Swann reissued an “outperform” rating and set a $97.00 price objective (up previously from $90.00) on shares of Sage Therapeutics in a report on Tuesday, June 20th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Sage Therapeutics currently has an average rating of “Buy” and an average target price of $86.77.

Shares of Sage Therapeutics (NASDAQ SAGE) opened at 64.81 on Friday. Sage Therapeutics has a 52-week low of $38.30 and a 52-week high of $90.80. The firm’s market capitalization is $2.43 billion. The company’s 50 day moving average price is $81.85 and its 200 day moving average price is $74.87.

A number of hedge funds have recently made changes to their positions in SAGE. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Sage Therapeutics by 11.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 138 shares in the last quarter. Turner Investments LLC bought a new position in Sage Therapeutics in the 2nd quarter valued at $159,000. Dubuque Bank & Trust Co. bought a new position in Sage Therapeutics in the 2nd quarter valued at $167,000. Canada Pension Plan Investment Board bought a new position in Sage Therapeutics in the 2nd quarter valued at $175,000. Finally, Ameritas Investment Partners Inc. bought a new position in Sage Therapeutics in the 1st quarter valued at $180,000.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.